312 related articles for article (PubMed ID: 26062758)
1. Cost-benefit analysis: newborn screening for inborn errors of metabolism in Lebanon.
Khneisser I; Adib S; Assaad S; Megarbane A; Karam P
J Med Screen; 2015 Dec; 22(4):182-6. PubMed ID: 26062758
[TBL] [Abstract][Full Text] [Related]
2. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
[TBL] [Abstract][Full Text] [Related]
3. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
[TBL] [Abstract][Full Text] [Related]
4. Newborn screening for inborn errors of metabolism: a systematic review.
Seymour CA; Thomason MJ; Chalmers RA; Addison GM; Bain MD; Cockburn F; Littlejohns P; Lord J; Wilcox AH
Health Technol Assess; 1997; 1(11):i-iv, 1-95. PubMed ID: 9483156
[TBL] [Abstract][Full Text] [Related]
5. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening.
Schoen EJ; Baker JC; Colby CJ; To TT
Pediatrics; 2002 Oct; 110(4):781-6. PubMed ID: 12359795
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S
Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
Cipriano LE; Rupar CA; Zaric GS
Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
[TBL] [Abstract][Full Text] [Related]
8. Institutional experience of newborn screening for inborn metabolism disorders by tandem MS in the Turkish population.
Demirelce Ö; Aksungar FB; Saral NY; Kilercik M; Serteser M; Unsal I
J Pediatr Endocrinol Metab; 2020 May; 33(6):703-711. PubMed ID: 32469332
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and therapeutic monitoring of inborn errors of metabolism in 100,077 newborns from Jining city in China.
Yang CJ; Wei N; Li M; Xie K; Li JQ; Huang CG; Xiao YS; Liu WH; Chen XG
BMC Pediatr; 2018 Mar; 18(1):110. PubMed ID: 29534692
[TBL] [Abstract][Full Text] [Related]
10. Screening newborns for inborn errors of metabolism by tandem mass spectrometry.
Wilcken B; Wiley V; Hammond J; Carpenter K
N Engl J Med; 2003 Jun; 348(23):2304-12. PubMed ID: 12788994
[TBL] [Abstract][Full Text] [Related]
11. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland.
Autti-Rämö I; Mäkelä M; Sintonen H; Koskinen H; Laajalahti L; Halila R; Kääriäinen H; Lapatto R; Näntö-Salonen K; Pulkki K; Renlund M; Salo M; Tyni T
Acta Paediatr; 2005 Aug; 94(8):1126-36. PubMed ID: 16188860
[TBL] [Abstract][Full Text] [Related]
12. Expanded newborn screening for inborn errors of metabolism by tandem mass spectrometry in newborns from Xinxiang city in China.
Ma S; Guo Q; Zhang Z; He Z; Yue A; Song Z; Zhao Q; Wang X; Sun R
J Clin Lab Anal; 2020 May; 34(5):e23159. PubMed ID: 31916308
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of tandem mass spectrometry newborn screening in Australia.
Norman R; Haas M; Chaplin M; Joy P; Wilcken B
Pediatrics; 2009 Feb; 123(2):451-7. PubMed ID: 19171609
[TBL] [Abstract][Full Text] [Related]
14. Tandem mass spectrometry and newborn screening: pilot data and review.
Filiano JJ; Bellimer SG; Kunz PL
Pediatr Neurol; 2002 Mar; 26(3):201-4. PubMed ID: 11955927
[TBL] [Abstract][Full Text] [Related]
15. Incidence of inborn errors of metabolism detected by tandem mass spectrometry in China: A census of over seven million newborns between 2016 and 2017.
Deng K; Zhu J; Yu E; Xiang L; Yuan X; Yao Y; Li X; Liu H
J Med Screen; 2021 Sep; 28(3):223-229. PubMed ID: 33241759
[TBL] [Abstract][Full Text] [Related]
16. The failure to diagnose inborn errors of metabolism in New Zealand: the case for expanded newborn screening.
Wilson C; Kerruish NJ; Wilcken B; Wiltshire E; Webster D
N Z Med J; 2007 Sep; 120(1262):U2727. PubMed ID: 17891215
[TBL] [Abstract][Full Text] [Related]
17. International cooperation in the expansion of a newborn screening programme in Lebanon: a possible model for other programmes.
Khneisser I; Adib SM; Megarbane A; Lukacs Z
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S441-6. PubMed ID: 19016345
[TBL] [Abstract][Full Text] [Related]
18. Expanded newborn screening using tandem mass spectrometry.
Fearing MK; Levy HL
Adv Pediatr; 2003; 50():81-111. PubMed ID: 14626484
[No Abstract] [Full Text] [Related]
19. Expanded newborn metabolic screening programme in Hong Kong: a three-year journey.
Chong SC; Law LK; Hui J; Lai CY; Leung TY; Yuen YP
Hong Kong Med J; 2017 Oct; 23(5):489-96. PubMed ID: 28862145
[TBL] [Abstract][Full Text] [Related]
20. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report.
Yoon HR; Lee KR; Kang S; Lee DH; Yoo HW; Min WK; Cho DH; Shin SM; Kim J; Song J; Yoon HJ; Seo S; Hahn SH
Clin Chim Acta; 2005 Apr; 354(1-2):167-80. PubMed ID: 15748614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
